ArticleThe Lancet. Respiratory medicine2021

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.

Luana Calabrò et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.